Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.51 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.42 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.41 |
| ▸ | MGAM | O43451 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3904545 | 0.82 | RAB9A (0.47) | GAAKMT2ACDK2GRM4SMN1; SMN2 | |
| SCHEMBL956877 | 0.78 | GRM4 (0.49) | CDK2GRM4SMN1; SMN2NPC1RAB9A | |
| SCHEMBL29887392 | 0.74 | GAA (1.00) | GAAMAPK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL20583237 | 0.74 | RAB9A (0.55) | GAACDK2GRM4SMN1; SMN2NPC1 | |
| SCHEMBL11887696 | 0.74 | GAA (1.00) | GAAMAPK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL2201618 | 0.73 | POLB (0.52) | GAAMAPK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL15522472 | 0.73 | LMNA (0.50) | KMT2AMEN1L3MBTL1MAPTHPGD | |
| SCHEMBL231018 | 0.73 | POLB (0.52) | GAAMAPK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL28927156 | 0.71 | KMT2A (0.53) | GAAMAPK1KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL30107608 | 0.71 | KMT2A (0.53) | GAAMAPK1KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9192603-B2 | Heterocyclic sulfone mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction | VANDERBILT UNIVERSITY (US) | 2015-11-24 | — | — | US | disclosed |
| US-20130158078-A1 | Heterocyclic Sulfone MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | VANDERBILT UNIVERSITY (US) | 2013-06-20 | — | — | US | disclosed |
| EP-2568809-A1 | HETEROCYCLIC SULFONE MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | Vanderbilt University (US) | 2013-03-20 | — | — | EP | disclosed |
| WO-2011143466-A1 | HETEROCYCLIC SULFONE MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION | VANDERBILT UNIVERSITY (US) | 2011-11-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158078-A1 | Heterocyclic Sulfone MGLUR4 Allosteric Potentiators, Compositions, and Methods of Treating Neurological Dysfunction | GRM4, GRIK4, GRIA4 | GAA 3196/4885MAPK1 2318/4885KMT2A 2028/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.